Insider filing
Traded Nov 19 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Planned for Nov 19, 2026 · Notice filed Nov 19, 2026
An Insmed officer told the SEC about a plan to sell $14.7M of Insmed shares around Nov 19, 2026. The shares were not acquired as compensation. That is a tiny part of all Insmed shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
None found in footnotes
Only flagged when a footnote says so; never inferred
Insider filing
Traded Nov 19 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Insider filing
Traded Nov 19 · filed 1 day later
Derivative exercise or conversion — not an open-market buy.
Orlov S Nicole Schaeffer (Chief People Strategy Officer) sold ~$1.25M of Insmed
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.